Relmada Therapeutics Inc (RLMD) concluded trading on Thursday at a closing price of $0.37, with 3.01 million shares of worth about $1.11 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -87.71% during that period and on December 12, 2024 the price saw a loss of about -11.38%. Currently the company’s common shares owned by public are about 30.17M shares, out of which, 25.17M shares are available for trading.
Stock saw a price change of -17.78% in past 5 days and over the past one month there was a price change of -88.79%. Year-to-date (YTD), RLMD shares are showing a performance of -91.06% which decreased to -84.90% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.42 but also hit the highest price of $7.22 during that period. The average intraday trading volume for Relmada Therapeutics Inc shares is 710.59K. The stock is currently trading -82.08% below its 20-day simple moving average (SMA20), while that difference is down -87.22% for SMA50 and it goes to -89.46% lower than SMA200.
Relmada Therapeutics Inc (NASDAQ: RLMD) currently have 30.17M outstanding shares and institutions hold larger chunk of about 41.26% of that.
The stock has a current market capitalization of $11.17M and its 3Y-monthly beta is at 0.35. It has posted earnings per share of -$2.87 in the same period. It has Quick Ratio of 6.89 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for RLMD, volatility over the week remained 11.67% while standing at 11.85% over the month.
Stock’s fiscal year EPS is expected to rise by 16.46% while it is estimated to increase by 58.15% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Mizuho on December 05, 2024 offering a Neutral rating for the stock and assigned a target price range of between $23 and $1 to it. Coverage by Jefferies stated Relmada Therapeutics Inc (RLMD) stock as a Buy in their note to investors on September 17, 2024, suggesting a price target of $13 for the stock. On June 05, 2024, Goldman Downgrade their recommendations, while on October 14, 2022, Truist Downgrade their ratings for the stock with a price target of $10. Stock get a Neutral rating from Guggenheim on October 14, 2022.
